Application of mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process

A technology of mevalonate and oocytes, applied in the field of bioengineering, can solve problems such as unclear

Inactive Publication Date: 2021-04-20
NANJING DRUM TOWER HOSPITAL
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

FOH is also used as a raw material for vitamin synthesis drugs, which can induce apoptosis in a variety of tumor cell lines, so its derivatives have beco

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process
  • Application of mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process
  • Application of mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0044]Example 1

[0045]This embodiment provides a medicament that improves the quality of aging ovarian oocytes and splitting processes, which contains 10 μmol / L leaf-free diaphragust (GGOH) in vitro maturation medium, and its group is 1 shown.

[0046]Table 1 Composition of components of in vitro mature medium containing GGOH

[0047] ingredient Volume / quality Final concentration BSA 0.12g3mg / ml Phemymycin mixture 400μL FSH 5μL 50IU / L LH 5μL 10IU / L Sodium pyruvate 100μL 0.23 mmol / L Glutamide 400μL 2 mmol / L M19939.082ml GgOH storage solution dissolved in anhydrous ethanol (50 mmol / L) 8μL 10μmol / L End volume 40ml

[0048]Application This in vitro maturation medium containing GgOH improves the quality and decay split process of aging ovarian oocytes, adding modes and experimental processes such asfigure 1 Down:

[0049](1) October C57BL / 6 fever intraperitoneal injection 10 Iu PMSG, and the ovaries were separated from the L15 medium, and the ovarium was transferred t...

Example Embodiment

[0059]Example 2

[0060]This embodiment provides a medicament that improves the quality of aging ovarian oocytes and the split process, which is shown in vitro maturation medium containing 20 μmol / L Fiiiol (FOH), and the group is shown in Table 2. .

[0061]Table 2 Composition of Components of in vitro mature medium containing FOH

[0062] ingredient Volume / quality Final concentration BSA 0.12g3mg / ml Phemymycin mixture 400μL FSH 5μL 50IU / L LH 5μL 10IU / L Sodium pyruvate 100μL 0.23 mmol / L Glutamide 400μL 2 mmol / L M19939.074ml FOH storage fluid dissolved in anhydrous ethanol (50 mmol / L) 16μL 20μmol / L End volume 40ml

[0063]Application of this FOH-containing in vitro mature medium to improve the quality and decay split process of aging ovarian oocytes:

[0064](1) October C57BL / 6 fever intraperitoneal injection 10 Iu PMSG, and the ovaries were separated from the L15 medium, and the ovarium was transferred to M2 medium, and the 1ml syringe was punctured by the sinus fol...

Example Embodiment

[0073]Example 3

[0074]This embodiment provides a medicament that improves the quality of aging ovarian oocytes and the split process, which is anhydrous ethanol injection preparation in which fragrant fragrant leaf alcohol (GgOH) is soluble, and the method of producing GgOH is dissolved. The 50 mmol / l GgOH reservoir was prepared in anhydrous ethanol, which was a GgOH anhydrous ethanol solution injection preparation.

[0075]Application of the GGOH anhydrous ethanol solution injection preparation improves the quality of aging ovarian oocytes and decreased split processes:

[0076](1) September decadency C57BL6 mice, divided into 2 groups (anhydrous ethanol solution) and GGOH (GgOH anhydrous ethanol solution injection preparation), administration daily, according to 40 mg / kg The body weight was taken with the control group and the GgOH group injection preparation, and the sterile physiological saline was diluted 10 times after intraperitoneal injection, 30 days of continuous treatment, s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process. The mevalonic acid metabolic intermediate product is geranyl geraniol or farnesol. One medicine is an in-vitro maturation culture medium containing the mevalonic acid metabolic intermediate product, the first polar body emission rate of mature oocytes can be significantly increased, and the abnormal rate of meiosis can be reduced. The other medicine is an absolute ethyl alcohol injection preparation with the dissolved mevalonic acid metabolic intermediate product, ovary weight, ovary indexes and the number of follicles at all levels can be remarkably increased, the PB1 emission rate of oocytes is remarkably increased after administration, and the chromosome/spindle abnormal rate of MII oocytes of superovulation and COCs in-vitro maturation is remarkably reduced.

Description

technical field [0001] The invention belongs to the technical field of bioengineering and relates to the application of mevalonate metabolic intermediates in the preparation of medicines for improving the quality of aging ovarian oocytes and the progress of meiosis. Background technique [0002] Women's ovarian function generally begins to decline from the age of 35, mainly manifested in a decrease in the number of follicles and a decrease in the quality of oocytes. The fertility problems of older women have attracted more and more attention. Chromosomal abnormalities in oocytes of advanced women with age increase are the main reasons for the decrease in pregnancy rate and increase in miscarriage. During the process of meiosis, aging oocytes are more prone to chromosomal lag and premature sister chromatid segregation. The proportion of aneuploid and triploid female oocytes was significantly increased. Previous studies have shown that drugs that improve mitochondrial functio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/045A61P15/00
Inventor 丁利军李朝军孙海翔刘传明
Owner NANJING DRUM TOWER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap